Results 11 to 20 of about 59,669 (311)

Hydroxychloroquine and COVID-19 [PDF]

Postgraduate Medical Journal, 2020
AbstractHydroxychloroquine and chloroquine are medications that have been used for a long time. Their most common use is for the treatment and prophylaxis of malaria. However, these antimalarial drugs are known to also have anti-inflammatory and antiviral effects and are used for several chronic diseases such as systemic lupus erythematosus with low ...
Sinha, Neeraj, Balayla, Galit
openaire   +3 more sources

Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: a multi-center observational study

BMC Infectious Diseases, 2021
Background Hydroxychloroquine has not been associated with improved survival among hospitalized COVID-19 patients in the majority of observational studies and similarly was not identified as an effective prophylaxis following exposure in a prospective ...
Andrew Ip, Jaeil Ahn, Yizhao Zhou, Andre H. Goy, Eric Hansen, Andrew L. Pecora, Brittany A. Sinclaire, Urszula Bednarz, Michael Marafelias, Ihor S. Sawczuk, Joseph P. Underwood, David M. Walker, Rajiv Prasad, Robert L. Sweeney, Marie G. Ponce, Samuel La Capra, Frank J. Cunningham, Arthur G. Calise, Bradley L. Pulver, Dominic Ruocco, Greggory E. Mojares, Michael P. Eagan, Kristy L. Ziontz, Paul Mastrokyriakos, Stuart L. Goldberg   +24 more
doaj   +1 more source

Hydroxychloroquine and Antimalarials [PDF]

The Journal of Rheumatology, 2019
We read the editorial by Sandhu, et al1 about antimalarial-induced cardiomyopathy in systemic lupus erythematosus2, and we want to point out some inaccuracies in the brief review of the history of antimalarials that they presented.
LUIS CAMINAL-MONTERO, SILVIA SUÁREZ-DÍAZ   +1 more
openaire   +3 more sources

Hydroxychloroquine-related hyperpigmentation

Rheumatology, 2021
International ...
Muller, Romain, Jarrot, Pierre André, Kaplanski, Gilles   +2 more
openaire   +3 more sources

Older patients with COVID‐19 and neuropsychiatric conditions: A study of risk factors for mortality

Brain and Behavior, Volume 12, Issue 12, December 2022., 2022
Abstract Background Little is known about risk factors for mortality in older patients with COVID‐19 and neuropsychiatric conditions. Methods We conducted a multicentric retrospective observational study at Assistance Publique‐Hôpitaux de Paris. We selected inpatients aged 70 years or older, with COVID‐19 and preexisting neuropsychiatric comorbidities
Vi‐Huong Nguyen‐Michel, Marion Houot, Cécile Delorme, Aude Sangaré, Ana Gales, Valerio Frazzini, Aurélie Hanin, Djamal Aissani, Thanh Trân, Bruno Oquendo, Flora Ketz, Carmelo Lafuente‐Lafuente, Christel Oasi, Kiyoka Kinugawa, Gaëlle Ouvrard, Renata Ursu, Bertrand Degos, Benjamin Rohaut, Sophie Demeret, Virginie Lambrecq, Vincent Navarro, Emmanuel Fournier, Jean‐Christophe Corvol, Alaina Borden   +23 more
wiley   +1 more source

COVID‐19 and myasthenia gravis: A review of neurological implications of the SARS‐COV‐2

Brain and Behavior, Volume 12, Issue 12, December 2022., 2022
Abstract Introduction This review highlights the potential mechanisms of neuromuscular manifestation of COVID‐19, especially myasthenia gravis (MG). Methods An extensive literature search was conducted by two independent investigators using PubMed/MEDLINE and Google Scholar from its inception to December 2020. Results Exacerbations of clinical symptoms
Syed Muhammad Ismail Shah, Farah Yasmin, Roha Saeed Memon, Nadia Nazir Jatoi, Ilma Saleh Savul, Sana Kazmi, Syed Abdullah Monawwer, Muhammad Daim Bin Zafar, Muhammad Sohaib Asghar, Muhammad Junaid Tahir, Ka Yiu Lee   +10 more
wiley   +1 more source

Hydroxychloroquine Blood Levels Predict Hydroxychloroquine Retinopathy

Arthritis & Rheumatology, 2020
ObjectiveIn 2016, the American Academy of Ophthalmology (AAO) changed the recommended daily dose of hydroxychloroquine (HCQ) from 6.5 mg/kg to <5 mg/kg. However, it is not clear that the lower prescribed dose of HCQ will have the same efficacy for systemic lupus erythematosus (SLE) activity or the same role in protecting against cardiovascular risk ...
Michelle Petri, Marwa Elkhalifa, Jessica Li, Laurence S. Magder, Daniel W. Goldman   +4 more
openaire   +4 more sources

TGIF1 overexpression promotes glioma progression and worsens patient prognosis

Cancer Medicine, Volume 11, Issue 24, Page 5113-5128, December 2022., 2022
This study is the first to comprehensively analyze and reveal TGIF1, as a new oncogene, is closely related to the malignancy‐related phenotype of glioma, and that TGIF1 could be an independent risk factor for poor prognosis of glioma, which is expected to become a new target for individualized treatment of glioma patients.
Baoya Wang, Qiong Ma, Xuelin Wang, Kunshan Guo, Zhendong Liu, Gang Li   +5 more
wiley   +1 more source

Hydroxychloroquine: a comprehensive review and its controversial role in coronavirus disease 2019

Annals of Medicine, 2021
Hydroxychloroquine, initially used as an antimalarial, is used as an immunomodulatory and anti-inflammatory agent for the management of autoimmune and rheumatic diseases such as systemic lupus erythematosus.
Pankaj Bansal, Amandeep Goyal, Austin Cusick, Shubham Lahan, Harpal S. Dhaliwal, Poonam Bhyan, Pradnya Brijmohan Bhattad, Fawad Aslam, Sagar Ranka, Tarun Dalia, Lovely Chhabra, Devang Sanghavi, Bhavin Sonani, John M. Davis   +13 more
doaj   +1 more source

Hydroxychloroquine-induced Hyperpigmentation [PDF]

The Journal of Rheumatology, 2020
About 10–25% of patients with systemic lupus erythematosus (SLE) managed with antimalarials will develop cutaneous hyperpigmentation, and although the majority of such cases is attributed to chloroquine, hydroxychloroquine (HCQ) is also implicated and is likely underrecognized1.
Amir Bajoghli, Gabriela Hernandez, Michael A. Cardis   +2 more
openaire   +3 more sources